1. Medtech Insight
  2. >>Business
  3. >>R&D
  4. >>Clinical Trials

InSightec’s Focused Ultrasound Shows Early, Positive Data For Disabling Tremor

The results are an encouraging sign not only for the company but also for the novel device development model employed by the trial’s sponsor, the Focused Ultrasound Foundation.

InSightec Ltd.’s ExAblate Neuro magnetic resonance focused ultrasound system showed promise as a treatment for severe tremors in early-stage data reported this week. The results are an encouraging sign for the company and the novel device development model employed by the trial’s sponsor, the Focused Ultrasound Foundation.

Results of the 15-patient trial

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Government-Backed UK Network Enhances Access To Clinical Trials

 
• By Vibha Sharma

The UK government expects that its new nation-wide network will enable companies to set up clinical trials more quickly and expand access to diverse patient populations across the National Health Service.

SetPoint Medical Raises $140M: Pipeline Expansion And Multiple Sclerosis Clinical Trial On Horizon

 
• By Natasha Barrow

SetPoint Medical secured US FDA approval for its vagus nerve neuromodulation device to treat RA. Now, the start-up is tasked with convincing both rheumatologist and surgeons to adopt its technology over or alongside biologic drugs. CEO Murthy Simhambhatla talks exit strategy plans.

German Health Researchers Prep for Possible Disruptions to PubMed, ClinicalTrials.gov

 
• By Elizabeth Orr and Francesca Bruce

IQWiG, Germany’s health technology assessment body, is making contingency plans in case key US resources it relies on for information retrieval, when conducting benefit assessments of new medicines, become unavailable.